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Methods: This retrospective observational study included adults with GNRB onset within 100
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isodes of GNRB were collected from patients’ medical charts. Those having polymicrobial
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ment was the most common surgical procedure in patients with GNRB after CVS (44.9%). Pro-
phylaxis antibiotics were ampicillin/sulbactam (76.9%), and vancomycin (12.8%). The crude 90-
day mortality rate was 21.8%, and the mean Acute Physiology and Chronic Health Evaluation II
score was 15.6 (range, 3e39). In 34.6% of patients, the same GNR species were isolated from
other samples within 30 days of GNRB occurrence. Multivariate analysis indicated that P. aer-
uginosa bacteremia [odds ratio (OR), 175; confidence interval (CI), 2.40e1270; p Z 0.0182],
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Gram-negative rod bacteremia (GNRB) after cardiovascular
surgery (CVS) is a serious complication associated with
morbidity and mortality.1,2 However, no studies have sys-
tematically studied GNRB after CVS. Infections after CVS,
such as surgical site infection and mediastinitis, are often
caused by Staphylococcus spp.3e5 Fowler et al5 reported
that in patients with bacteremia that developed within 90
days after CVS, Staphylococcus spp. accounted for 75.8% of
causative organisms of bacteremia episodes and Gram-
negative rods (GNRs) accounted for 18.8%. GNRB may be a
frequent cause of inappropriate treatment, because GNRs
are underestimated in bacteremia after CVS.
We aimed to describe the demographical, clinical,
microbiological, and prognostic factors of GNRB after CVS.Methods
Study design
We conducted a retrospective observational study at Tokyo
Women’s Medical University Hospital in Tokyo, Japan, a
1423-bed university-affiliated hospital, with 200 beds in the
cardiovascular department, which is one of the largest in-
stitutes for cardiovascular disease. Clinical data regarding
episodes of GNRB were collected from patients’ medical
charts. All adult cases of GNRB after CVS from April 2004 to
May 2013 were included. The Ethics Committee at Tokyo
Women’s Medical University Hospital approved the study
protocol (approval number 3013).
Definitions
An episode of GNRB was defined as an adult patient with at
least one positive blood culture yielding any GNRs. Blood
samples were drawn under sterile conditions and processed
using the BACTEC 9240 system (Becton Dickinson Diagnostic
Instrument Systems, Towson, MD, USA) until March 11,
2011, and the BacT/ALERT 3D system (bioMe´rieux, Marcy
l’Etoile, France) from April 2011 to May 2013. Blood sam-
ples were incubated for up to 7 days. GNRs were identified
using GNR-Combo NC6.11J, NC6.12J, and NC3.12J (Siemens
Healthcare Diagnostics, Deerfield, IL, USA). We defined the
date of GNRB diagnosis as the day of sampling of positive
blood culture. We enrolled patients for whom the number
of days from CVS to GNRB diagnosis was within 100 days. If
the patient had many episodes of GNRB, we included all
episodes of GNRB and analyzed each episode separately.
Basically ampicillin/sulbactam was used as prophylaxis
antibiotics, and vancomycin was chosen for patients with b-Tago S, et al., Gram-negative ro
iology, Immunology and Infectionlactam allergy or Methicillin-resistant Staphylococcus
aureus colonization. The empiric antibiotic was considered
“appropriate,” if the treatment regimens included at least
one antibiotic active in vitro against all identified patho-
gens. We considered antimicrobial therapy “inappropriate”
if the drugs used did not have in vitro activity against the
isolated strain, or if the patient did not receive any anti-
biotics empirically. If in vitro activity of the antibiotic was
not tested, we defined it as “unknown.” Bentall procedure
was included in graft replacement (thoracic). We evaluated
the species isolated from other sites within 30 days from
when the blood culture was performed. If there was more
than one sample from the same site, only the latest sample
was enrolled.
Study population
Patients were observed from the day of GNRB diagnosis to
the 90-day follow-up. The following data were obtained for
all patients: age, sex, comorbidities, type of surgery, use of
medical devices, source of bacteremia, empirical or
definitive antibiotics, time period from surgery to bacter-
emia development, culture samples from any sites, Acute
Physiology and Chronic Health Evaluation (APACHE) II score
at the day blood cultures were performed, and crude
mortality in 90 days. We determined the source of bacter-
emia after reviewing medical records written by the pri-
mary physicians and receiving agreement from the
infectious disease physician. Exclusion criteria were pa-
tients younger than 20 years, being enrolled in another
clinical trial, the presence of polymicrobial bacteremia
with a bacterium other than a GNR, and the surgery type
being catheter surgery.
Statistical analysis
Continuous data were compared using the Student t test
and categorical data using Fisher’s exact tests. Data were
considered statistically correlated when p < 0.05. Multi-
variate analysis was used to determine the independent risk
factors associated with mortality using forward stepwise
logistic regression. All variables with p < 0.1 in univariate
analysis were entered into the multivariate model. Statis-




Among 2017 CVS patients, 434 developed bacteremia.
Gram-positive cocci were present in 267 (61.5%) patientsd bacteremia after cardiovascular surgery: Clinical features and
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16 patients, and Enterococcus spp. in 14 patients), GNRs in
135 (31.1%) patients, Gram-positive rods in 29 (6.7%) pa-
tients, and Gram-negative cocci in three (0.7%) patients.
The incidence of GNRB after CVS was 6.7% (nZ 135). Of the
135 patients with GNRB, 78 were included in this study. Of
the 135 patients, 57 were excluded because of being
enrolled in other clinical trials (n Z 21), bacteremia onset
being > 100 days after CVS (n Z 28), and polymicrobial
bacteremia with a bacterium other than a GNR (n Z 8).
Demographic and clinical characteristics of the 78 cases (61
survivors and 17 deaths) with GNRB after CVS are shown in
Table 1. The mean age of the patients was 64.9  11.2
years. Of the 78 patients, 35 (44.9%) underwent graft
replacement, 18 (23.1%) isolated coronary artery bypass
grafting, four (5.1%) coronary artery bypass grafting plus
valve replacement, 19 (24.4%) isolated valve replacement,
and two (2.6%) other surgery (1 removal of the left atrial
myxoma, and 1 resection of pulmonary arterial aneurysm
and closure of atrial septal defect).
Comorbidities included hypertension (43.6%), diabetes
mellitus (25.6%), and chronic kidney disease (24.4%). Eight
(10.3%) patients had previous CVS. At the onset of bacter-
emia, these patients had previously undergone urinary
catheter placement (55.1%), central venous catheter
placement (47.4%), intubation (43.6%), treatment with a
vasopressor (32.1%), and dialysis (26.9%). The sources of
bacteremia were the urinary tract (16.7%), mediastinum
(10.3%), and peritoneum (6.4%); however, sources could not
be identified in 56.4% (n Z 44) of patients. Seventy-seven
of 78 patients (98.7%) had prophylaxis antibiotics.
Reported prophylaxis antibiotics were ampicillin/sul-
bactam (n Z 60; 76.9%), vancomycin (n Z 10; 12.8%),
ampicillin/sulbactam plus amikacin (n Z 2), cefazolin
(n Z 1), vancomycin plus meropenem (n Z 1), ampicillin
(n Z 1), arbekacin (n Z 1), and unknown (n Z 2). The
median period from the day of surgery to the day of blood
culture was 11 days (range, 2e94 days). GNRB occurred < 7
days after CVS in 26.9% of patients and < 14 days in 62.8%
(Figure 1). A total of 89 GNRs were identified in the 78
patients (Table 2). Klebsiella spp. (n Z 22; 24.7%), Pseu-
domonas aeruginosa (n Z 21; 23.6%), Enterobacter spp.
(nZ 18; 20.2%), and Escherichia coli (nZ 11; 12.4%) were
the most commonly isolated organisms, accounting for
80.9% of all bacteremia episodes. There were three
extended-spectrum b-lactamase-producing Klebsiella sp.
(3.4%) and two carbapenem-resistant P. aeruginosa (2.2%).
The empiric antibiotics were appropriate in 70.5% (nZ 55),
inappropriate in 14.1% (n Z 11), and unknown in 15.4%
(n Z 12). The mean APACHE II score was 15.6 (range,
3e39), the crude 14-day mortality rate was 11.5%, and the
crude 90-day mortality rate was 21.8%. The results of uni-
variate and multivariate analyses are shown in Table 1. The
incidence of GNRB< 7 days after CVS was 47.1% in the
death group and 21.3% in the survival group (pZ 0.0603). P.
aeruginosa bacteremia [odds ratio (OR), 175; confidence
interval (CI), 2.40e1270; p Z 0.0182], APACHE II scores of
 25 (OR, 76.2; CI, 1.04e5580; p Z 0.0479), and vanco-
mycin prophylaxis (OR, 45.4; CI, 1.02e202; p Z 0.0488)
were independent prognostic factors associated with death
due to GNRB after CVS. We compared the characteristics of
patients with P. aeruginosa (nZ 21) and non-P. aeruginosaPlease cite this article in press as: Tago S, et al., Gram-negative ro
prognostic factors, Journal of Microbiology, Immunology and Infectionbacteremia (n Z 57). Statistically significant differences
(p < 0.05) were shown in mortality rate (P. aeruginosa
group 50.0% vs. non-P. aeruginosa group 12.1%,
pZ 0.0171), APACHE II score (30.0% vs. 5.2%, pZ 0.00979),
thoracic graft replacement (10.0% vs. 32.8%, p Z 0.0447),
the incidence of GNRB< 7 days after CVS (45.0% vs. 19.0%,
p Z 0.0203), and dialysis (50.0% vs. 19.0%, p Z 0.0203).
The P. aeruginosa group had more frequency of hyperten-
sion (60.0% vs. 36.2%), diabetes mellitus (35.0% vs. 20.7%),
chronic kidney diseases (40.0% vs. 19.0%), urinary cathe-
terization (70.0% vs. 17.2%), and central venous catheteri-
zation (55.5% vs. 43.1%).
Same species from other sites
In 27 (34.6%) patients, the same species were isolated from
40 samples other than the blood within 30 days from when
the blood culture was performed (Table 3). The same or-
ganisms were isolated from sputum (n Z 19; 47.5%),
catheter tips (nZ 8; 20.0%), urine (nZ 5; 12.5%), pharynx
exudate (n Z 5; 12.5%), skin (n Z 2; 5.0%), and otorrhea
(n Z 1; 2.5%). In 27 patients, drug susceptibility of the
organism isolated from the samples was the same as that of
the blood in five (18.5%) patients, partially the same in two
(7.4%) patients, and all different in 20 (74.1%) patients.
Discussion
This study analyzed the demographical, clinical, and
microbiological features, as well as the outcomes and
prognostic factors of GNRB after CVS. To the best of our
knowledge, this is the first paper to report on GNRB after
CVS specifically.
The incidence of GNRB after CVS observed among our
patients was 6.7%. There were no such reports to describe
the incidence of Gram-negative bacteremia after CVS. The
frequency of GNR to all causative organisms of bacteremia
was 31.4% in our study. The reported frequency of GNR
after CVS varies from 18.8% to 60.0%.2,5
The mortality rate of GNRB after CVS observed among
our patients was 21.8%. In a previous study, the mortality
rate of GNRB was estimated at 12% in non-neutropenic
patients6 and 53.3% in intensive care unit patients.7 In our
study, the 14- and 90-day mortality rates were estimated;
however, which day mortality rate used was not clearly
described in previous studies.
Our study suggests that graft replacement was the most
common surgical procedure in patients with GNRB after
CVS. Among the 35 patients who underwent graft replace-
ment, 14 (40.0%) underwent thoracoabdominal or abdom-
inal aortic grafting. Therefore, we evaluated the reasons
why GNRB occurs after graft replacement. Koratzanis et al8
reported that graft replacement for abdominal aortic
aneurysm causes bacterial translocation. The ischemia/
reperfusion of gut mucosa during surgery may promote
translocation of bacteria.9 Further, microinjury to organs in
the abdomen, such as the kidney or intestines, during sur-
gery can be the entry site of GNRs, although there were no
apparent cases.
We identified that 62.8% of GNRB cases occurred < 14
days after CVS. The high GNRB incidence in the early phased bacteremia after cardiovascular surgery: Clinical features and
(2015), http://dx.doi.org/10.1016/j.jmii.2015.07.008











64.9  11.2 64.6  10.8 65.0  11.4
Age >65 y 49 11 (64.7) 38 (62.3) 1
Sex (male) 53 12 (70.6) 41 (67.2) 1
BMI > 25 16 4 (23.5) 12 (19.7) 0.74
EF < 40 6 3 (17.6) 3 (4.9) 0.127
APACHE n score  25 9 7 (41.2) 2 (3.3) 0.000203 76.2 (1.04e5580)*
Type of surgery
-Graft replacement 35 6 (35.3) 29 (47.5) 0.42
Thoracic 21 2 (11.8) 19 (31.1) 0.134
Thoracoabdominal 8 3 (17.6) 5 (8.2) 0.362
Abdominal 6 1 (5.9) 5 (8.2) 0.58
-CABG þ valve replacement 4 1 (5.9) 3 (4.9) 1
-Isolated CABG 18 6 (35.3) 12 (19.7) 0.201
-Isolated valve procedure 19 4 (23.5) 15 (24.6) 1
-Others 2 0 2 (3.3) 1
Comorbidity
-Hypertension 34 9 (52.9) 25 (41.0) 0.418
-Diabetes mellitus 20 4 (23.5) 16 (26.2) 1
-Chronic kidney disease 19 4 (23.5) 15 (24.6) 1
-Hyperlipidemia 14 2 (11.8) 12 (19.7) 0.722
-Previous cardiovascular disease 8 3 (17.6) 5 (8.2) 0.362
-Malignancy 7 1 (5.9) 6 (9.8) 1
-Cerebrovascular disorder 7 0 7 (11.5) 0.336
-Bronchial asthma 3 1 (5.9) 2 (3.3) 0.527
Devices
-Urinary catheter 43 13 (76.5) 30 (49.2) 0.0565
-Central venous catheter 37 11 (64.7) 26 (42.6) 0.169
-Intubation 34 15 (88.2) 19 (31.1) 0.0000405
-Vasopressor 25 9 (52.9) 16 (26.2) 0.0452
-Dialysis 21 9 (52.9) 12 (19.7) 0.0117
-IABP 4 2 (11.8) 2 (3.3) 0.205
Organism
-Klebsiella spp. 22 3 (17.6) 19 (31.1) 0.368
-Pseudomonas aeruginosa 21 10 (58.8) 11 (18.0) 0.00171 175 (2.4e1270)*
-Enterobacter spp. 18 4 (23.5) 14 (23.0) 1
-Escherichia coli 11 1 (5.9) 10 (16.4) 0.439
Source of bacteremia
-Urinary tract 13 0 13 (21.3) 0.0599
-Mediastinum 8 2 (11.8) 6 (9.8) 1
-Peritoneum 5 0 5 (8.2) 0.58
-Lung 4 1 (5.9) 3 (4.9) 1
-Catheter-related 3 0 3 (4.9) 1
-Skin and soft tissue 1 0 1 (1.6) 1
-Unknown 44 14 (82.4) 30 (49.2) 0.0251
Prophylactic use of antimicrobial
-Ampicillin/sulbactam 60 9 (52.9) 51 (83.6) 0.0188
-Vancomycin 10 5 (29.4) 5 (8.2) 0.035 45.4 (1.02e202)*
Empirical antimicrobial therapy
-Carbapenems 25 7 (41.2) 18 (29.5) 0.389
-Fluoroquinolone 4 2 (11.8) 2 (3.3) 0.205
Appropriate empirical therapy 55 10 (58.8) 45 (73.8) 0.018
From CVS to GNRB < 7 d 21 8 (47.1) 13 (21.3) 0.0603
The same species isolated from other
sites within 30 d
27 7 (41.2) 20 (32.8) 0.571
*p < 0.05.
APACHE Z Acute Physiology and Chronic Health Evaluation; BMI Z body mass index; CABG Z coronary artery bypass graft;
CIZ confidence interval; CVSZ cardiovascular surgery; EFZ ejection fraction; GNRBZ Gram-negative rod bacteremia, IABPZ intra-
aortic balloon pump; OR Z odds ratio; SD Z standard deviation.
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Figure 1. Occurrence and fatality rates of Gram-negative
rod bacteremia. GNRB Z Gram-negative rod bacteremia.
Table 2 Gram-negative rods isolated from blood
(N Z 89)
Organism n (%)
Klebsiella spp. 22 (24.7)
Pseudomonas aeruginosa 21 (23.6)
Enterobacter spp. 18 (20.2)
Escherichia coli 11 (12.4)
Serratia marcescens 5 (5.6)
Acinetobacter spp. 3 (3.4)
Stenotrophomonas maltophilia 3 (3.4)
Prevotella spp. 2 (2.1)
Citrobacter spp. 1 (1.1)
Aeromonas spp. 1 (1.1)
Proteus spp. 1 (1.1)
Bacteroides spp. 1 (1.1)
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such as urinary catheters, ventilators, or venous catheters
that may cause urinary tract infection, ventilator-
associated pneumonia, or catheter-related blood stream
infection due to GNR. Although Gram-positive coccus may
be the major causative organism, we should consider GNR
as the causative organism when administering empirical
antibiotic therapy, if we suspect bacteremia in the early
phase after CVS. The median period from the day of surgery
to the day of blood culture (occurrence of GNRB) was 11
days. The incidence of GNRB< 7 days after CVS was 47.1%
in the death group and 21.3% in the survival group
(p Z 0.0603). Early-phase GNRB after CVS may be associ-
ated with a poor prognosis.Table 3 Same organism from other samples (NZ 40)
Samples n (%)
Sputum 19 (47.5)
Catheter tip 8 (20.0)
Urine 5 (12.5)
Pharynx exudate 5 (12.5)
Skin 2 (5.0)
Otorrhea 1 (2.5)
Please cite this article in press as: Tago S, et al., Gram-negative ro
prognostic factors, Journal of Microbiology, Immunology and InfectionWhen GNR is isolated from the blood culture, empirical
antibiotic treatment must be initiated immediately,
considering the species and antibiotic susceptibility of GNR.
In a study, van Eck van der Sluijs et al10 reported that an
intravascular catheter tip colonized with Gram-negative
microorganism was predictive of subsequent bacteremia
in 19% of cases. In 34.6% of our patients, the same species
were isolated from other samples within 30 days from the
day the blood culture was performed. The most frequent
sample was sputum, which accounted for 47.5% of all
samples. As pneumoniae was determined to be the source
of infection in only five cases, we speculate that unrecog-
nized ventilator-associated pneumonia or a minor injury to
the tracheal mucosa due to intubation may be the source of
infection. Antibiotic susceptibility of other samples was the
same in 18.5% patients, partially the same in 7.4%, and all
different in 74.1%. It revealed that the antibiotic suscep-
tibility of GNRs previously isolated from other sites was not
in accordance with the susceptibility of GNRs isolated from
the blood cultures in the current study. It is possible to
assume this for two reasons. First, the new resistance
occurred because of exposure of the same GNR strain to
antibiotics. Second, the same species (other strain) was
acquired from the hospital environment. Clonal delineation
is needed. Our results indicate that GNRs isolated from any
other sites (i.e., sputum) may help identify the species of
GNR causing bacteremia.
In this study, sources of infection were not identified in
as much as 55.8% of patients, which is not usual.7,11 After
CVS, patients are often intubated or sedated, making it
difficult to identify symptoms and determine the identity of
the infectious organ. Moreover, surgical site infection,
mediastinitis, and catheter-related blood stream infection
are generally caused by Staphylococcus spp.; therefore,
clinicians may not consider them a source of GNRB. Ac-
cording to the literature, Gram-negative organisms account
for 22e28.3% of mediastinitis,12,13 and 20e30% of surgical
site infections.3,14
This study provides evidence that several factors are
associated with increased mortality from GNRB after CVS.
These factors include P. aeruginosa bacteremia, APACHE II
scores of  25, and vancomycin for prophylaxis. APACHE II
scores of  25 and vancomycin for prophylaxis have not
been reported as the prognostic factors in previous studies.
Previous reports of Pseudomonas bacteremia also have
noted high mortality.15 In our study, the patients with P.
aeruginosa bacteremia might have had poor prognostic
factors, as they had an increased frequency of hyperten-
sion, diabetes mellitus, and chronic kidney disease. More-
over, they also had an increased frequency of urinary
catheterization, central venous catheterization, and dial-
ysis. These medical devices could be risk factors for the
infections caused by GNR. Further, as P. aeruginosa can be
spread on hands of health care workers or by equipment
that gets contaminated and is not properly cleaned, the
patients with the devices had more chances to get P. aer-
uginosa. We emphasize the importance of infection control
practices, especially hand hygiene and environmental
cleaning, for preventing the spread of P. aeruginosa to
reduce the mortality of patients after CVS.
According to the Infectious Diseases Society of America
guideline for antimicrobial prophylaxis, vancomycin ord bacteremia after cardiovascular surgery: Clinical features and
(2015), http://dx.doi.org/10.1016/j.jmii.2015.07.008
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agent for b-lactam-allergic patients undergoing cardiac
procedures, and addition of Gram-negative antibiotics for
extended coverage may be prudent when Gram-negative
pathogens are concerned.16 Our study showed that vanco-
mycin for prophylaxis is associated with high mortality in
multivariable analysis, which indicates that prophylaxis
antibiotic for CVS (i.e., graft replacement surgery) might
cover Gram-negative organisms, too. Further investigation
is needed.
Knaus et al17 showed that nosocomial mortality of pa-
tients after surgery, whose APACHE II score was in the range
of 25e29, is 37%. Conversely, our study showed that in
patients with GNRB after CVS, an APACHE II score in the
range of 25e29 indicates a 77.8% mortality rate. The high
mortality observed in our study may have been caused by
the hosts’ unstable condition after CVS. We conclude that
the APACHE II score suggests a higher mortality rate in pa-
tients with GNRB after CVS than in general populations, on
the basis of the findings of a previous study.17
Previous studies showed that the factors associated with
higher overall mortality included acute respiratory distress
syndrome, septic shock, disseminated intravascular coag-
ulation, anuria, the presence of a central venous catheter,
the presence of a urinary catheter, an infection of unknown
origin, inappropriate antibiotic treatment,6 azotemia, and
low or normal temperature.15 In our study, the patients
with urinary catheterization, an infection of unknown
origin, and inappropriate empiric therapy have a high
mortality, although not significant. However, the presence
of a central venous catheter was not related to a high
mortality.
This study has two limitations. First, the study involved a
retrospective analysis with a small sample size at a single
center. Second, the 90-day mortality included all deaths,
which may have been due to not only GNRB, but also other
factors such as low cardiac function, arrhythmia, or
bleeding.
In conclusion, graft replacement was the most common
surgical procedure in patients with GNRB after CVS. Early-
phase GNRB after CVS may be associated with a poor
prognosis. We identified that P. aeruginosa bacteremia,
APACHE II scores of  25, and vancomycin for prophylaxis
are independent prognostic factors associated with death
due to GNRB after CVS. Empirical antibiotics covering GNRs,
including P. aeruginosa, should be considered if bacteremia
is suspected in unstable patients after CVS.
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